Product image of Linagliptin Hexal (Linagliptin) supplied by GNH India

Linagliptin Hexal

Active Ingredient:
Linagliptin
Origin:
EU

Linagliptin Hexal (Linagliptin)

Linagliptin, the active ingredient in Linagliptin Hexal, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used as part of a comprehensive diabetes treatment plan.

GNH India supplies Linagliptin Hexal as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide in accordance with EU regulatory standards.

Manufacturer / TM Owner

Hexal Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin is a DPP‑4 inhibitor used in the treatment of type 2 diabetes mellitus.

  • Type 2 diabetes mellitus (monotherapy): reduces blood glucose when used alone.
  • Type 2 diabetes mellitus (combination therapy): enhances glycaemic control when added to metformin, sulfonylureas or insulin.
  • Type 2 diabetes mellitus (adjunct to lifestyle): supports diet and exercise in achieving target HbA1c.

How It Works

  • Linagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the breakdown of the incretin hormones GLP‑1 and GIP. Elevated incretin levels increase glucose‑dependent insulin secretion and suppress glucagon release, thereby improving post‑prandial and fasting blood glucose levels without causing hypoglycaemia in the absence of other secretagogues.

Side Effects

Common Side Effects

  • Nasopharyngitis: mild upper respiratory tract inflammation.
  • Headache: transient, mild to moderate intensity.
  • Dizziness: occasional light‑headed sensation.
  • Gastrointestinal upset: includes nausea, abdominal discomfort.
  • Back pain: musculoskeletal discomfort.
  • Arthralgia: joint pain without swelling.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain with elevated enzymes.
  • Severe hypersensitivity: rash, angioedema, or anaphylaxis.
  • Hepatic injury: abnormal liver function tests.
  • Bullous skin reactions: blistering dermatoses.
  • Severe allergic reactions: including Stevens‑Johnson syndrome.
  • Angioedema: swelling of face, lips, or airway.

Precautions & Warnings

Linagliptin should be used with clinical caution in the following situations:

  • Renal impairment: assess renal function before initiating therapy.
  • Hepatic impairment: monitor liver enzymes regularly.
  • Hypersensitivity: discontinue if rash, angioedema, or severe allergic reaction occurs.
  • Pregnancy and lactation: only if clearly needed after risk‑benefit evaluation.
  • Cardiovascular disease: monitor for any unexpected cardiac events.
  • Store at ambient temperature: keep below 25 °C, retain in the original packaging, and protect from moisture and light.

Avoid Interactions

Linagliptin may interact with several medicines; monitoring is advised.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure.
  • Strong CYP3A4 inducers (e.g., rifampicin): may reduce linagliptin exposure.
  • Concurrent insulin secretagogues (e.g., sulfonylureas): heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely)

  • Diuretics: may affect blood glucose monitoring accuracy.
  • Rifampin (moderate inducer): may lower linagliptin plasma levels.
  • Antihypertensives: observe blood pressure changes when combined with improved glycaemic control.

Frequently Asked Questions

Linagliptin Hexal is prescribed for the treatment of type 2 diabetes mellitus in adults. It helps lower blood glucose levels by enhancing the body’s own incretin response, and it can be used alone or together with other antidiabetic agents as part of a comprehensive diabetes management plan.

Linagliptin works by selectively inhibiting the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition prevents the breakdown of incretin hormones GLP‑1 and GIP, leading to increased insulin secretion and reduced glucagon release in a glucose‑dependent manner, thereby improving overall glycaemic control.

The specific dose of Linagliptin Hexal is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal and hepatic function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Linagliptin should only be used during pregnancy or lactation if the potential benefit justifies the potential risk to the fetus or infant. The decision must be made by a qualified healthcare provider after a thorough risk‑benefit assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin shares the same class mechanism as other DPP‑4 inhibitors but is distinguished by its primarily non‑renal elimination, allowing use without dose adjustment in patients with renal impairment. Efficacy and safety profiles are comparable, though individual tolerability may vary.

Linagliptin Hexal tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original blister pack, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Linagliptin Hexal is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional.

Serious risks, though rare, include pancreatitis, severe hypersensitivity reactions such as angioedema or Stevens‑Johnson syndrome, and significant hepatic injury. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling of the face or throat, or signs of liver dysfunction.

Linagliptin Hexal is contraindicated in individuals with a known hypersensitivity to linagliptin or any of the tablet’s excipients. It should also be avoided in patients who have experienced severe allergic reactions to other DPP‑4 inhibitors.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT